One longtime Eastern Kentucky dentist is flourishing in an entirely different career during his retirement — moonshining.

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...

The second edition of the Mash Ball, held at The St. Regis Mumbai on October 5, 2025, unfolded as a glittering celebration of art, fashion, and social impact. Conceptualised by Shalini Passi, founder ...

Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent obesity related comorbidities Akero Therapeutics’s FGF21 ...

Every product was carefully curated by an Esquire editor. We may earn a commission from these links. Here’s how we test products and why you should trust us. Swatch has launched the Mission to ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

From the beginning, the allure and hype around the MoonSwatch has been driven by designed scarcity more than affordability. Swatch could easily produce more, but doing so would tarnish the vibe, so to ...

Roche has scooped up 89bio and its phase III FGF21 analogue pegozafermin, as drug developers continue to race to advance new drugs for the liver disease metabolic dysfunction-associated ...

Downtown PKB hosted the annual Monster Mash event Thursday evening in the green space beside Discovery World at 900 Market St. in downtown Parkersburg. The free event was a family-friendly Halloween ...

Few dinners are as widely loved as sausages, mash, and gravy, and chef Tom Kerridge makes his even more wintery with a simple ingredient swap. There are numerous ways to make classic dinners more ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...